FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
02 mai 2016 16h05 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Race to Yes Underscores Evidence Presented at FDA Advisory Committee Meeting for Duchenne Muscular Dystrophy Drug Eteplirsen
27 avr. 2016 13h38 HE
|
The Race to Yes
Organization Urges FDA to Use the Evidence Presented by Dozens of Scientists, Physicians, Patients and Advocates as Required by 2012 FDASIA Act for Conditional Approval Experts Remind Duchenne...
Race to Yes Calls on FDA Advisory Committee: Carefully Consider Data and Recommend Duchenne Drug Approval Based on Data and Direct Experience of Children and Clinicians
22 avr. 2016 12h49 HE
|
The Race to Yes
WASHINGTON, April 22, 2016 (GLOBE NEWSWIRE) -- In what is predicted to be the largest turnout in history at an FDA Advisory Committee meeting, more than 800 clinicians, researchers, patients and...
Summit Reports Positive Interim Data From Ongoing Phase 1 Clinical Trial Testing a New Formulation of SMT C1100 in Patients With DMD
30 mars 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
15 mars 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
FibroGen Announces Fiscal 2015 Financial Results
29 févr. 2016 16h02 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the year ended December...
Summit Therapeutics to Participate in SunTrust Robinson Humphrey’s 2016 Orphan Drug Day
17 févr. 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
21 janv. 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy
06 janv. 2016 17h46 HE
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”) announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical...
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
17 déc. 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...